Aptargroup Inc (ATR)

How it makes money

AptarGroup generates revenue by designing and manufacturing specialized dispensing technologies and components that are integrated into customers' products during development and qualification stages. Revenue streams include nasal spray pumps, metered-dose inhalers, elastomeric components for injectable drug delivery, aerosol valves, and dispensing closures. Once a component is designed into a customer's product and qualified for their filling line or regulatory program, customers face significant switching costs. The company serves a broadly diversified customer base with no single customer exceeding 4% of net sales.

Revenue by segment

AptarGroup's moat rests primarily on switching costs created by regulatory qualification and customer integration. Once a component is designed into a customer's product and qualified on the filling line or in a regulated pharmaceutical program, customers face significant friction switching to competitors. The company reinforces this through technical expertise in proprietary component design, regulatory know-how, and active material science that competitors cannot easily replicate. However, the advantage is narrow rather than wide because competitors with sufficient regulatory expertise and manufacturing capabilities can eventually develop alternatives, particularly in less specialized closures segments.

AptarGroup's demand exhibits moderate cyclicality. The Pharma segment is relatively defensive, driven by prescription drug volumes, new drug approvals, and the ongoing GLP-1 diabetes and obesity drug boom which creates demand for injectable delivery systems. The Beauty segment shows greater sensitivity to consumer spending and prestige fragrance demand. The Closures segment is moderately cyclical, tied to food, beverage, and consumer product consumption. Overall, the company's diversified portfolio across regulated pharmaceuticals and consumer goods provides some insulation from economic downturns, though margin pressure occurs during commodity inflation.

Key risks

• FDA Investigations and Regulatory Compliance — The Aptar Pharma segment is subject to investigations, audits, and proceedings initiated by the FDA and other regulatory agencies. Regulatory violations or product quality issues could result in substantial compliance costs, product recalls, manufacturing restrictions, or loss of customers.
• Supply Chain Disruption and Single-Source Supplier Reliance — AptarGroup faces significant operational risks due to reliance on single-source suppliers for certain critical materials, particularly in the pharmaceutical segment. Supply disruptions, whether from geopolitical events, natural disasters, or supplier financial difficulties, could adversely impact the company's ability to deliver products and fulfill customer commitments.
• Raw Material Price Volatility — The cost of raw materials, particularly plastic resins and rubber, is volatile and subject to commodity price fluctuations. If material costs increase and cannot be offset by price increases to customers or productivity improvements, operating margins could compress significantly, particularly in the lower-margin Closures segment.
• Tariffs and Trade Restrictions — Tariffs imposed on imports, particularly on imports from China, Canada, Mexico and other countries, could increase the cost of raw materials and components. If tariff increases require raising prices for products, demand could decline, customers could be lost, and competitive position could be harmed in key markets.
• Competition and Pricing Pressure — AptarGroup competes with larger diversified manufacturers and specialized dispensing companies. Competitors with greater resources, established relationships, or lower-cost manufacturing capabilities could gain market share, particularly in non-specialized closures segments where differentiation is lower.

Top customers account for 4% of revenue

No single customer or group of affiliated customers accounts for greater than 4% of AptarGroup's 2025 net sales. With approximately 5,000 customers served across diversified pharmaceutical, beauty, and consumer product markets, the company has a well-distributed customer base that mitigates dependency risk on any individual customer or customer group.